Pricing Log in Create free account

BridgeBio Pharma, Inc. (BBIO) vs Jazz Pharmaceuticals PLC (JAZZ)

BridgeBio Pharma, Inc. and Jazz Pharmaceuticals PLC are both Biotechnology companies. BridgeBio Pharma, Inc. and Jazz Pharmaceuticals PLC are of similar size ($14.6B and $14.5B). BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Jazz Pharmaceuticals PLC trades at 62.6×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 167.3% against 13.5%. Jazz Pharmaceuticals PLC has the higher net margin (4.37% vs −62.6%) and the higher return on invested capital (3.86% vs 0.00%). Across the 17 metrics below, Jazz Pharmaceuticals PLC leads on 9 and BridgeBio Pharma, Inc. on 8.

Valuation

Metric BBIO JAZZ Biotechnology median
P/E n/m 62.55 10.26
P/S 15.49 3.12 9.18
P/B n/m 3.51 2.05
Price to free cash flow n/m 22.16 24.81
EV/EBITDA n/m 15.24 0.65
EV/Sales 15.90 3.70 8.98
Earnings yield (4.07%) 1.60% (34.89%)
Free cash flow yield (2.58%) 4.51% (24.52%)

Profitability

Metric BBIO JAZZ Biotechnology median
Gross margin 94.34% 89.09% 65.16%
Operating margin (38.52%) 9.03% 0.00%
Net margin (62.62%) 4.37% 0.00%
Free cash flow margin (39.11%) 14.08% 0.00%
Return on equity 26.22% 5.05% (50.12%)
Return on assets (37.48%) 1.76% (45.60%)
Return on invested capital 0.00% 3.86% 0.00%

Growth

Metric BBIO JAZZ Biotechnology median
Revenue growth (TTM) 167.27% 13.48% 6.26%
EPS growth (last fiscal year) (31.25%) (167.51%) 29.88%
Revenue growth, 5-year CAGR 127.44% 12.54% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BBIO JAZZ Biotechnology median
Debt to equity (1.17) 1.33 0.00
Current ratio 2.09 1.82 4.89
Net debt to EBITDA (2.47) 10.96 1.01

Dividend

Metric BBIO JAZZ Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BBIO JAZZ Biotechnology median
Market cap 14.47b 14.59b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack